1
|
Markey K, Macfarlane A, Manning M. Time to re-envisage culturally responsive care: Intersection of participatory health research and implementation science. J Adv Nurs 2023; 79:4228-4237. [PMID: 37548346 DOI: 10.1111/jan.15821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2023] [Revised: 07/18/2023] [Accepted: 07/27/2023] [Indexed: 08/08/2023]
Abstract
AIM In the context of widening societal diversity, culturally and linguistically diverse patients continue to experience inequities in healthcare access and deficiencies in standards of nursing care. Re-framing culturally responsive care as a complex intervention spanning multiple interacting factors at micro, meso and macro levels is an essential prerequisite for addressing knowledge translation gaps into everyday nursing practice. To this end, this paper proposes and explicates the potential of applying synergistic participatory implementation methodologies for developing effective implementation strategies with impact at individual and wider structural levels. DESIGN Discussion Paper. DATA SOURCES A co-design case study is presented as an example of combining normalization process theory and participatory learning and action to investigate and support the implementation of culturally responsive care in general practice nursing. IMPLICATIONS FOR NURSING Enacting culturally responsive health care is inherently complex in that it is influenced by multiple interacting factors. Viewing culturally responsive care as a complex intervention and incorporating a synergistic participatory implementation science approach offers possibilities for addressing the documented shortcomings in the implementation of culturally responsive nursing care. CONCLUSION There is a need to move away from conventional approaches to conceptualizing and generating evidence on culturally responsive care. Incorporating participatory implementation methodologies can provide a new lens to investigate and support whole system implementation strategies. IMPACT The combination of participatory and implementation methodologies is both theoretically and empirically informed. Engaging stakeholders in the co-design and co-production of evidence and solutions to long standing problems has the potential to increase the likelihood of influencing iterative and sustainable implementation and changes to clinical practice and systems. PATIENT OR PUBLIC CONTRIBUTION This work is part of a wider programme of participatory health research on migrant health, partnering with a non-governmental organization that supports migrants.
Collapse
Affiliation(s)
- K Markey
- Department of Nursing and Midwifery, Health Research Institute, University of Limerick, Limerick, Ireland
| | - A Macfarlane
- School of Medicine, Health Research Institute, University of Limerick, Limerick, Ireland
| | - M Manning
- School of Allied Health, Health Research Institute, University of Limerick, Limerick, Ireland
| |
Collapse
|
2
|
Hodzic RK, Manning M, Copeland A, Scott-Jones F, Van Dyck G, Schneider L, Waugh W, Plotkin E, Boehmer L. Identifying Key Barriers for Radiation Oncology Financial Advocacy Programs. Int J Radiat Oncol Biol Phys 2023; 117:e592. [PMID: 37785791 DOI: 10.1016/j.ijrobp.2023.06.1943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Financial toxicity is a devastating outcome for patients with cancer and can impact their treatment adherence and health outcomes. One survey reveals that most radiation oncologists are "very concerned" with the negative impact treatment-related costs have on patients, and another survey found that more than 20 percent of patients experience financial toxicity related to their radiation therapy treatment. Financial advocates within cancer programs and practices can help mitigate patients' financial toxicity by supporting shared decision-making and helping with treatment cost planning. In 2022, ACCC set out to explore how financial advocates in radiation oncology provide financial navigation to patients with cancer and address the challenges they may face. Identify barriers to financial toxicity mitigation and treatment access challenges for patients with cancer undergoing radiation therapy. MATERIALS/METHODS ACCC worked with an expert multidisciplinary Financial Advocacy Network Advisory Committee to conduct two, semi-structured discussion sessions on financial advocacy in radiation oncology. Prepared discussion topics included challenges and opportunities in delivering financial advocacy services, financial barriers to care and strategies to mitigate financial toxicity, and processes for prior authorizations and claim denials in the radiation oncology setting. RESULTS Twenty-one participants attended the first session, and 17 participants attended the second session. Participants included financial navigators and counselors, oncology social workers, nurse navigators, and cancer program or practice administrators. Three major challenges emerged from both sessions: (1) Inadequate financial assistance from independent, charitable foundations to help pay for patients' deductibles, additional radiation treatment out-of-pocket costs, and care-related transportation costs. (2) Lack of best practices to handle prior authorization and avoid denials. (3) Lack of preparedness for changes imposed by the Radiation Oncology (RO) Model, which would impact care planning. CONCLUSION Many cancer programs and practices have implemented financial advocacy services but remain restricted in the available assistance for radiation therapy patients. Radiation therapy represents a significant component of anti-cancer treatment and addressing the lack of financial support for patients is critical to improving patients' treatment adherence and health outcomes. Payment policies must be reformed to address complex prior authorization requirements and patients would benefit from greater financial support for radiation treatment and costs of wrap-around supportive services.
Collapse
Affiliation(s)
| | | | | | | | | | | | - W Waugh
- Southern Ohio Medical Center, Portsmouth, OH
| | - E Plotkin
- Association of Community Cancer Centers, Rockville, MD
| | - L Boehmer
- Association of Community Cancer Centers, Rockville, MD
| |
Collapse
|
3
|
Bernstein J, Anderson J, Manning M, Tachdjian R, Bajcic P, Rodino F, Wang S, Lumry W. PRELIMINARY RETROSPECTIVE ANALYSIS OF PATIENT OUTCOMES ASSOCIATED WITH SUBCUTANEOUS C1INH PROPHYLAXIS FOR HEREDITARY ANGIOEDEMA. Ann Allergy Asthma Immunol 2022. [DOI: 10.1016/j.anai.2022.08.588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
4
|
Prabhu R, Dhakal R, Vaslow Z, Dan T, Mishra M, Murphy E, Patel T, Asher A, Yang K, Manning M, Stern J, Patel A, Wardak Z, Woodworth G, Chao S, Mohammadi A, Burri S. Preoperative Radiosurgery for Resected Brain Metastases: The PROPS-BM Multicenter Cohort Study. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Anderson J, Sheridan W, Desai B, Tomita D, Manning M. D005 CONSISTENTLY LOW HEREDITARY ANGIOEDEMA (HAE) ATTACK RATES OBSERVED IN US PATIENTS TREATED WITH BEROTRALSTAT. Ann Allergy Asthma Immunol 2021. [DOI: 10.1016/j.anai.2021.08.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
6
|
Manning M, Greenfield S. University students' understanding and options of eating disorders: A qualitative study. Eur J Public Health 2021. [DOI: 10.1093/eurpub/ckab165.575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Eating disorders (EDs) affect 1.25 million people in the UK. Evidence suggests the public perceive EDs as a female issue and display stigma and poor mental health literacy (MHL) towards EDs. There is a high prevalence of EDs in university populations, so it is important to determine the MHL of this at-risk group. Qualitative research exploring the MHL of this population is incomplete.
Aims
To explore university students' beliefs and opinions of EDs, their knowledge of symptoms, treatment and help sources and how these are influenced by biological sex.
Methods
A qualitative study, using semi-structured interviews with seven male and seven female participants. Interviews were analysed using inductive thematic analysis. Analyst triangulation and member validation occurred.
Results
Analysis revealed six themes, each with subthemes: ED characteristics, causes, body image, seeking help, stigma and awareness. Students displayed poor awareness towards ED signs and symptoms, causes and help sources. Students were not stigmatising towards EDs, but many perceived them as a female problem and believed society to be stigmatising. Many referenced informal sources of information such as social media and expressed a desire for ED teaching. Sex did not have a significant influence on knowledge or opinions of EDs in this study, however there were some differences, for example some males were more likely to see EDs as a weakness and to perceive themselves as having low levels of knowledge.
Conclusions
University students show poor awareness of certain aspects of ED-MHL including help sources and symptom recognition. Although students were not stigmatising of EDs themselves, many perceived high levels of public stigma. This, alongside poor knowledge, may delay help-seeking. Campaigns educating students and the public about EDs would aid earlier diagnosis, improving long-term outcomes. Further research into awareness and knowledge in other populations would be beneficial.
Key messages
University students interviewed perceived high levels of public stigma around eating disorders, although not stimatising themselves. Campaigns educating students and the public about EDs would aid earlier diagnosis, improving long-term outcomes.
Collapse
Affiliation(s)
- M Manning
- Medical School, University of Birmingham, Birmingham, UK
| | - S Greenfield
- Institute of Applied Health Research, University of Birmingham, Birmingham, UK
| |
Collapse
|
7
|
|
8
|
Riedl M, Cicardi M, Hao J, Lu P, Li H, Manning M, Bernstein J, Busse P, Tachdjian R, Gower R, Wedner H. P159 LONG-TERM EFFICACY OF LANADELUMAB: INTERIM RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY. Ann Allergy Asthma Immunol 2019. [DOI: 10.1016/j.anai.2019.08.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
9
|
Prabhu R, Turner B, Asher A, Marcrom S, Fiveash J, Foreman P, Press R, Patel K, Curran W, Breen W, Brown P, Jethwa K, Grills I, Arden J, Foster L, Manning M, Stern J, Soltys S, Burri S. A Multi-institutional Analysis of Patterns of Salvage Therapy for Leptomeningeal Disease after Surgical Resection and Radiosurgery for Brain Metastases. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
10
|
Manning M, Cykert S, Eng E, Walker P, Robertson L, Arya R, Jones N, Heron D. A Prospective Multi-Institutional Trial to Resolve Black-White Disparities in the Treatment of Early Stage Lung Cancer. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
11
|
Manning M, Liu H, Borden L, Woodruff H. Proposed Hydrogel Implant Quality Score (HIQS) for Prostate Radiotherapy. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
12
|
Prabhu R, Soltys S, Turner B, Marcrom S, Fiveash J, Foreman P, Press R, Patel K, Curran W, Breen W, Brown P, Jethwa K, Grills I, Arden J, Foster L, Manning M, Stern J, Asher A, Burri S. Patterns of Failure and Outcomes Based On Management of Leptomeningeal Disease after Surgical Resection and Radiosurgery for Brain Metastases: A Multi-Institutional Analysis. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.06.348] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
13
|
Zuraw B, Cicardi M, Jacobs J, Longhurst H, Lu P, Manning M, Shennak M, Soteres D, Wang Y, Zaragoza-Urdaz R. LANADELUMAB EXPOSURE DURING STEADY STATE: ACHIEVEMENT OF EFFECTIVE CONCENTRATIONS IN PATIENTS IN THE HELP STUDY. Ann Allergy Asthma Immunol 2018. [DOI: 10.1016/j.anai.2018.09.118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
14
|
Manning M, Caballero T, Hussain I, Feuersenger H, Chiao J, Jacobs I, Pragst I. LONG-TERM EFFICACY OF SUBCUTANEOUS C1 INHIBITOR IN PEDIATRIC PATIENTS WITH HEREDITARY ANGIOEDEMA. Ann Allergy Asthma Immunol 2018. [DOI: 10.1016/j.anai.2018.09.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
15
|
Manning M, Ashley E, Hayes L, Liu H, Sintay B. Dosimetric and 7-Year Biochemical Results with a Robotic Prostate Brachytherapy System. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
16
|
Riedl MA, Aygören-Pürsün E, Baker J, Farkas H, Anderson J, Bernstein J, Bouillet L, Busse P, Manning M, Magerl M, Gompels M, Huissoon AP, Longhurst H, Lumry W, Ritchie B, Shapiro R, Soteres D, Banerji A, Cancian M, Johnston DT, Craig T, Launay D, Li HH, Liebhaber M, Nickel T, Offenberger J, Rae W, Schrijvers R, Triggiani M, Wedner HJ, Dobo S, Cornpropst M, Clemons D, Fang L, Collis P, Sheridan W, Maurer M. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study. Allergy 2018; 73:1871-1880. [PMID: 29688579 PMCID: PMC6175137 DOI: 10.1111/all.13466] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/12/2018] [Indexed: 12/02/2022]
Abstract
Background Effective inhibition of plasma kallikrein may have significant benefits for patients with hereditary angioedema due to deficiency of C1 inhibitor (C1‐INH‐HAE) by reducing the frequency of angioedema attacks. Avoralstat is a small molecule inhibitor of plasma kallikrein. This study (OPuS‐2) evaluated the efficacy and safety of prophylactic avoralstat 300 or 500 mg compared with placebo. Methods OPuS‐2 was a Phase 3, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Subjects were administered avoralstat 300 mg, avoralstat 500 mg, or placebo orally 3 times per day for 12 weeks. The primary efficacy endpoint was the angioedema attack rate based on adjudicator‐confirmed attacks. Results A total of 110 subjects were randomized and dosed. The least squares (LS) mean attack rates per week were 0.589, 0.675, and 0.593 for subjects receiving avoralstat 500 mg, avoralstat 300 mg, and placebo, respectively. Overall, 1 subject in each of the avoralstat groups and no subjects in the placebo group were attack‐free during the 84‐day treatment period. The LS mean duration of all confirmed attacks was 25.4, 29.4, and 31.4 hours for the avoralstat 500 mg, avoralstat 300 mg, and placebo groups, respectively. Using the Angioedema Quality of Life Questionnaire (AE‐QoL), improved QoL was observed for the avoralstat 500 mg group compared with placebo. Avoralstat was generally safe and well tolerated. Conclusions Although this study did not demonstrate efficacy of avoralstat in preventing angioedema attacks in C1‐INH‐HAE, it provided evidence of shortened angioedema episodes and improved QoL in the avoralstat 500 mg treatment group compared with placebo.
Collapse
Affiliation(s)
- M. A. Riedl
- Division of Rheumatology; Allergy & Immunology; University of California San Diego; San Diego CA USA
| | - E. Aygören-Pürsün
- Department for Children and Adolescents; University Hospital Frankfurt; Frankfurt Germany
| | - J. Baker
- Baker Allergy Asthma Dermatology Research Center; Portland OR USA
| | - H. Farkas
- 3rd Department of Internal Medicine; Semmelweis University; Budapest Hungary
| | - J. Anderson
- Clinical Research Center of Alabama; Birmingham AL USA
| | - J. A. Bernstein
- Department of Internal Medicine; University of Cincinnati; Cincinnati OH USA
| | - L. Bouillet
- Internal Medicine; National Reference Centre of Angioedema; Grenoble University Hospital; Grenoble France
| | - P. Busse
- Division of Clinical Immunology and Allergy; Department of Medicine; Icahn School of Medicine at Mount Sinai; New York NY USA
| | - M. Manning
- Medical Research of Arizona; Allergy; Asthma & Immunology Associates; Scottsdale AZ USA
| | - M. Magerl
- Dermatology, Venerology and Allergology; Charite - Universitätsmedizin Berlin; Berlin Germany
| | - M. Gompels
- Immunology; North Bristol NHS Trust; Bristol UK
| | - A. P. Huissoon
- Department of Allergy and Immunology; Heartlands Hospital; Birmingham UK
| | - H. Longhurst
- Immunology; Addenbrookes Hospital; Cambridge University Hospitals; Cambridge UK
| | - W. Lumry
- Allergy and Asthma Research Associates Research Center; Dallas TX USA
| | - B. Ritchie
- Division of Hematology; Department of Medicine; University of Alberta; Edmonton AB Canada
| | - R. Shapiro
- Immunology; Midwest Immunology Clinic; Plymouth MN USA
| | - D. Soteres
- Asthma and Allergy Associates PC; Colorado Springs CO USA
| | - A. Banerji
- Division of Rheumatology; Allergy& Immunology; Department of Medicine; Massachusetts General Hospital; Harvard Medical School; Boston MA USA
| | - M. Cancian
- Department of Medicine; University of Padova; Padova Italy
| | | | - T. J. Craig
- Department of Medicine and Pediatrics; Penn State Hershey Allergy Asthma, and Immunology; Hershey PA USA
| | - D. Launay
- Internal Medicine; CHRU Lille; France France
| | - H. H. Li
- Institute for Asthma and Allergy; Chevy Chase MD USA
| | - M. Liebhaber
- Allergy and Immunology; Sansum Clinic; Santa Barbara CA USA
| | - T. Nickel
- Allergy & Immunology; Allergy Clinic of Tulsa; Tulsa OK USA
| | | | - W. Rae
- Allergy & Clinical Immunology; University Hospital Southampton NHS Foundation Trust; Southampton UK
| | - R. Schrijvers
- Laboratory of Clinical Immunology; KU Leuven; Leuven Belgium
| | - M. Triggiani
- Division of Allergy and Clinical Immunology; University of Salerno; Salerno Italy
| | - H. J. Wedner
- Division of Allergy and Immunology; Washington University School of Medicine; St. Louis MO USA
| | - S. Dobo
- Biocryst Pharmaceuticals; Durham NC USA
| | | | | | - L. Fang
- Statistics; PharStat, Inc.; Raleigh NC USA
| | - P. Collis
- Biocryst Pharmaceuticals; Durham NC USA
| | | | - M. Maurer
- Department of Dermatology and Allergy; Charité - Universitätsmedizin Berlin; Berlin Germany
| |
Collapse
|
17
|
Pollom RK, Lacaya LB, Ilag LL, Manning M. Efficacy and safety between Insulin Glargine Products (LY2963016 and Lantus®) in patients with T2DM: the ELEMENT 5 study. DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1641896] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- RK Pollom
- Eli Lilly and Company, Indianapolis, United States
| | - LB Lacaya
- Eli Lilly and Company, Indianapolis, United States
| | - LL Ilag
- Eli Lilly and Company, Indianapolis, United States
| | - M Manning
- Lilly Deutschland GmbH, Bad Homburg, Germany
| |
Collapse
|
18
|
Caridi T, Yoon J, Manning M, Cardella J, Spies J. Abstract No. 430 Repeat uterine artery embolization: update on indications and technical findings. J Vasc Interv Radiol 2018. [DOI: 10.1016/j.jvir.2018.01.475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
19
|
Lumry W, Bernstein J, Cicardi M, Zuraw B, Craig T, Caballero T, Farkas H, Anderson J, Jacobs J, Riedl M, Manning M, Banerji A, Gower R. P153 Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Ann Allergy Asthma Immunol 2017. [DOI: 10.1016/j.anai.2017.08.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
20
|
Craig T, Zuraw B, Lumry W, Bernstein J, Cicardi M, Anderson J, Jacobs J, Riedl M, Manning M, Banerji A. OR031 Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2017. [DOI: 10.1016/j.anai.2017.08.037] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
21
|
Bernstein J, Fridman M, Li H, Craig T, Manning M, Supina D, Feuersenger H, Machnig T, Krishnarajah G. P160 Indirect comparison of placebo-controlled trials of C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Ann Allergy Asthma Immunol 2017. [DOI: 10.1016/j.anai.2017.08.147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
22
|
Manning M, Cykert S, Eng E, Yee M, Robertson L, Hardy C, Schaal J, Heron D, Jones N, Foley K, Smith B, Alexandra L, Samuel C, Gizlice Z. Reducing Racial Disparities in Treatment for Early-Stage Lung Cancer With a Multimodal Intervention. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Maurer J, Wiant D, Liu H, Manning M, Sintay B. A Novel Algorithm for Rapid Generation of Single Isocenter Dynamic Conformal Arc Plans for Simultaneous Treatment of Multiple Brain Metastases. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.2370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
24
|
Staley EM, Carruba SS, Manning M, Pham HP, Williams LA, Marques MB, Locke JE, Lorenz RG. Anti-Blood Group Antibodies in Intravenous Immunoglobulin May Complicate Interpretation of Antibody Titers in ABO-Incompatible Transplantation. Am J Transplant 2016; 16:2483-6. [PMID: 26913485 DOI: 10.1111/ajt.13760] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2015] [Revised: 02/09/2016] [Accepted: 02/14/2016] [Indexed: 01/25/2023]
Abstract
Patients receiving ABO-incompatible (ABOi) kidney transplants are treated before and after transplant with combination therapy, such as intravenous immunoglobulin (IVIG) and therapeutic plasma exchange, to prevent allograft rejection by reducing anti-A and anti-B titers. Although generally considered safe, it is well known that commercial IVIG products contain detectable anti-A and anti-B, which can be associated with hemolysis. Different preparative manufacturing techniques during the production of IVIG affect ABO antibody levels in IVIG preparations; therefore, some manufacturers now use new methods to reduce anti-A/B levels at the preproduction stage. The variations in implementing these strategies creates the potential for significant variation in antibody titers between products and, in some cases, even between lots of the same IVIG product. We report a case of persistently elevated anti-A titers in an ABOi kidney transplant recipient associated with elevated ABO antibody titers present in the preparation of IVIG used at our facility.
Collapse
Affiliation(s)
- E M Staley
- Department of Pathology, University of Alabama at Birmingham, Birmingham, AL
| | - S S Carruba
- Pharmacy Department, University of Alabama at Birmingham, Birmingham, AL
| | - M Manning
- Pharmacy Department, University of Alabama at Birmingham, Birmingham, AL
| | - H P Pham
- Department of Pathology, University of Alabama at Birmingham, Birmingham, AL
| | - L A Williams
- Department of Pathology, University of Alabama at Birmingham, Birmingham, AL
| | - M B Marques
- Department of Pathology, University of Alabama at Birmingham, Birmingham, AL
| | - J E Locke
- Department of Surgery, University of Alabama at Birmingham, Birmingham, AL
| | - R G Lorenz
- Department of Pathology, University of Alabama at Birmingham, Birmingham, AL
| |
Collapse
|
25
|
Maurer J, Sintay B, Manning M, Wiant D, Liu H. SU-F-T-510: Single Isocenter Radiosurgery for the Simultaneous Treatment of Multiple Brain Metastases: Volumetric Modulated Arc Therapy Or Dynamic Conformal Arc? Med Phys 2016. [DOI: 10.1118/1.4956695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
26
|
Wiant D, Manning M, Liu H, Maurer J, Hayes T, Sintay B. SU-F-T-626: Intracranial SRS Re-Treatment Without Acquisition of New CT Images. Med Phys 2016. [DOI: 10.1118/1.4956811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
27
|
Maurer J, Liu H, Wiant D, Koch K, Manning M, Sintay B. SU-E-T-197: Comparing Quality Assurance Strategies for Single Isocenter Treatments of Multiple Brain Metastases. Med Phys 2015. [DOI: 10.1118/1.4924558] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
28
|
Liu H, Manning M, Sintay B, Maurer J, Hayes L, Wiant D. SU-E-T-177: Clinical Experience with Spirometer Guided Breath Hold Lung SBRT. Med Phys 2015. [DOI: 10.1118/1.4924538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
29
|
Manning M, Maurer J. SU-E-J-187: Management of Optic Organ Motion in Fractionated Stereotactic Radiotherapy. Med Phys 2015. [DOI: 10.1118/1.4924273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
30
|
Takhar S, Manning M, Eason A, Dix M, Periyasamy-Thandavan S, Padi R, Bieberich E, Hill W, Browning D, Ganapathy V, Thangaraju M, Schoenlein PV. Abstract B50: MEK inhibitors mount a two-pronged attack to kill estrogen receptor positive (ER+) breast cancer cells undergoing hormonal therapy: Attenuated autophagy and induction of apoptosis. Mol Cancer Res 2014. [DOI: 10.1158/1557-3125.rasonc14-b50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
In a recent study, we identified the dephosphorylated form of BimEL as a key death effector of antiestrogen treatment of ER+ breast cancer cells and further showed that MEK1/MAPK1/2 blockade was required to produce high levels of dephosphorylated BimEL, particularly under conditions of insulin like growth factor 1 (IGF1) stimulation (Periyasamy-Thandavan et al., Breast Cancer Res. 14, 2012). Studies by others have identified MEK1/MAPK1/2 activation as essential to autophagy, a catabolic process induced by multiple stresses including ROS, ceramide accumulation, and nutrient deprivation. Autophagy induction results in autophagosome formation, trafficking of damaged proteins and mitochondria to the autophagosomes, and ultimately fusion with the lysosomes resulting in autolysosome formation. The autolysosome and its contents are degraded by the hydrolytic enzymes of the lysosome. Of particular interest to antiestrogen treatment of breast cancer, we and others have shown that pro-survival autophagy facilitates the emergence of antiestrogen resistant breast cancer cells. Thus, we are keenly interested in how MEK1/MAPK1/2 signaling affects pro-survival autophagy and if MEK blockade would be an effective approach toward blocking pro-survival autophagy in ER+ breast cancer cells undergoing hormonal treatment. In this study, we hypothesized that the requirement of MEK1/MAPK1/2 for pro-survival autophagy is due, in part, to its role in blocking the intracellular accumulation of dephosphorylated BimEL. To test this hypothesis, we modulated the expression of dephosphorylated BimEL with either a BimEL cDNA expression vector, siRNA targeting of BimEL, or MEK1 blockade with the small molecule inhibitor U0126 and determined the levels of the autophagic flux in ER+ breast cancer cells undergoing antiestrogen treatment. The determination of autophagic flux was made by comparing the levels of two proteins involved in autophagy -the LC3 /Atg8 and p62 (SQSTM1) proteins- in cell populations undergoing the different treatments in the presence or absence of chloroquine (CQ). The lipidated form of LC3, designated LC3II, is typically increased in cells undergoing autophagy, facilitates the formation of the mature autophagosomal membranes, and is subsequently degraded in the autolysosome. The p62 protein is required for the delivery of ubiquitinated protein complexes to the autophagosome and is degraded along with the ubiquitinated complex of proteins. CQ is a lysosomotrophic agent routinely used in autophagic flux assays because it blocks the turnover of autolysosomes with accumulation of LC3 II and p62, allowing the total levels of LC3II and p62 to be ascertained under all treatment conditions. These studies showed that siRNA targeting of BimEL increased basal and tamoxifen-induced autophagy in ER+ MCF-7 breast cancer cells. In contrast, the overexpression of dephosphorylated BimEL led to an increase in LC3 II and p62 levels due to a significant attenuation of autophagic flux (approximately 50%) in antiestrogen-treated cell populations. Current studies are focused on the mechanism of BimEL-mediated blockade of pro-survival autophagy, with the long term goal of optimizing this “downstream effector” function of MEK1/MAPK1/2 blockade in ER+ breast cancer cells for improved therapeutic outcome.
Citation Format: S. Takhar, M. Manning, A. Eason, M. Dix, S. Periyasamy-Thandavan, R. Padi, E. Bieberich, W. Hill, D. Browning, V. Ganapathy, M. Thangaraju, P. V. Schoenlein. MEK inhibitors mount a two-pronged attack to kill estrogen receptor positive (ER+) breast cancer cells undergoing hormonal therapy: Attenuated autophagy and induction of apoptosis. [abstract]. In: Proceedings of the AACR Special Conference on RAS Oncogenes: From Biology to Therapy; Feb 24-27, 2014; Lake Buena Vista, FL. Philadelphia (PA): AACR; Mol Cancer Res 2014;12(12 Suppl):Abstract nr B50. doi: 10.1158/1557-3125.RASONC14-B50
Collapse
Affiliation(s)
- S. Takhar
- GRU Cancer Center, Georgia Regents University, Augusta, GA
| | - M. Manning
- GRU Cancer Center, Georgia Regents University, Augusta, GA
| | - A. Eason
- GRU Cancer Center, Georgia Regents University, Augusta, GA
| | - M. Dix
- GRU Cancer Center, Georgia Regents University, Augusta, GA
| | | | - R. Padi
- GRU Cancer Center, Georgia Regents University, Augusta, GA
| | - E. Bieberich
- GRU Cancer Center, Georgia Regents University, Augusta, GA
| | - W. Hill
- GRU Cancer Center, Georgia Regents University, Augusta, GA
| | - D. Browning
- GRU Cancer Center, Georgia Regents University, Augusta, GA
| | - V. Ganapathy
- GRU Cancer Center, Georgia Regents University, Augusta, GA
| | - M. Thangaraju
- GRU Cancer Center, Georgia Regents University, Augusta, GA
| | | |
Collapse
|
31
|
Manning M, Wiant D, Sintay B, Stern J. NT-21 * PRELIMINARY CLINICAL OUTCOMES FOLLOWING RAPID DELIVERY RADIOSURGERY FOR MULTIPLE BRAIN METASTASES. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou265.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Manning M, Sintay B, Wiant D, Ganem P, Moody J. An Overall Survival Comparison of Sub-Lobar Resection With Brachytherapy Versus Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
33
|
Jones KL, Hoyme HE, Robinson L, DelCampo M, Manning M, Chambers C, Yevtushok L, Zymak-Zakutnya N, Wertelecki W, Jones KL, Keen CL, Uriu-Adams JY, Coles C, Yevtushok L, Zymak-Zakutnya N, Wertelecki W, Keen CL, Uriu-Adams JY, Kable JA, Jones KL, Chambers CD, Kable J, Coles C, Chambers C, Keen C, Uriu-Adams J, Jones K, Yevtushok L, Wertelecki W. S21 * TOWARD A BETTER UNDERSTANDING OF THE SPECTRUM OF FETAL ALCOHOL SPECTRUM DISORDERS AND THE ROLE OF MATERNAL NUTRITION IN MODIFYING FETAL RISK. Alcohol Alcohol 2013. [DOI: 10.1093/alcalc/agt092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
34
|
Pursley J, Manning M, Sintay B, Terrell J, Maurer J, Yount C, Wiant D. SU-E-T-677: The Effects of Respiratory Motion in RapidArc Spinal Stereotactic Radiosurgery. Med Phys 2013. [DOI: 10.1118/1.4815104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
35
|
Klein MJK, Kuemin C, Tamulevicius T, Manning M, Wolf H. Note: a microfluidic chip setup for capillarity-assisted particle assembly. Rev Sci Instrum 2012; 83:086109. [PMID: 22938351 DOI: 10.1063/1.4749846] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
We developed a microfluidic chip setup for capillarity-assisted particle assembly (CAPA). A capillary bridge is formed between the aperture of a silicon chip and the assembly template. The bridge is fed with particle suspension through a microfluidic channel on the chip top side. With this setup, we can control the particle assembly location and tune the suspension composition during particle assembly. In this note, we describe the chip setup, the CAPA process using the microfluidic chip, and results of complex particle assemblies, such as composite particle arrays and particle gradients, that could not be obtained using a conventional CAPA setup.
Collapse
Affiliation(s)
- M J K Klein
- IBM Research - Zurich, IBM Research GmbH, 8803 Rüschlikon, Switzerland
| | | | | | | | | |
Collapse
|
36
|
Kapu NUS, Manning M, Hurley TB, Voigt J, Cosgrove DJ, Romaine CP. Surfactant-assisted pretreatment and enzymatic hydrolysis of spent mushroom compost for the production of sugars. Bioresour Technol 2012; 114:399-405. [PMID: 22459956 DOI: 10.1016/j.biortech.2012.02.139] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/19/2011] [Revised: 02/28/2012] [Accepted: 02/29/2012] [Indexed: 05/31/2023]
Abstract
Spent mushroom compost (SMC), a byproduct of commercial mushroom cultivation, poses serious environmental problems that have hampered the growth of this important agro-industry. In an effort to develop new applications for SMC, we explored its use as a feedstock for bioethanol production. SMC constitutes approximately 30%w/w polysaccharides, 66% of which is glucan. Following dilute-acid pretreatment and enzymatic hydrolysis, both in the presence of PEG 6000, 97% of glucan and 44% of xylan in SMC were converted into the corresponding monosaccharides. Incorporation of PEG 6000 reduced the cellulase requirement by 77%. Zwittergent 3-12 and 3-14 also significantly increased the efficacy of acid pretreatment and enzymatic hydrolysis. The use of SMC in bioethanol production represents a potential mitigation solution for the critical environmental issues associated with the stockpiling of the major byproduct of the mushroom industry.
Collapse
Affiliation(s)
- N U S Kapu
- Expansyn Technologies, Inc., 200 Innovation Boulevard, Suite 258-B, State College, PA 16803, USA
| | | | | | | | | | | |
Collapse
|
37
|
Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, Durroux T, Mouillac B, Corbani M, Guillon G. Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol 2012; 24:609-28. [PMID: 22375852 PMCID: PMC3490377 DOI: 10.1111/j.1365-2826.2012.02303.x] [Citation(s) in RCA: 308] [Impact Index Per Article: 25.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2012] [Revised: 02/17/2012] [Accepted: 02/17/2012] [Indexed: 01/08/2023]
Abstract
We recently reviewed the status of peptide and nonpeptide agonists and antagonists for the V(1a), V(1b) and V(2) receptors for arginine vasopressin (AVP) and the oxytocin receptor for oxytocin (OT). In the present review, we update the status of peptides and nonpeptides as: (i) research tools and (ii) therapeutic agents. We also present our recent findings on the design of fluorescent ligands for V(1b) receptor localisation and for OT receptor dimerisation. We note the exciting discoveries regarding two novel naturally occurring analogues of OT. Recent reports of a selective VP V(1a) agonist and a selective OT agonist point to the continued therapeutic potential of peptides in this field. To date, only two nonpeptides, the V(2) /V(1a) antagonist, conivaptan and the V(2) antagonist tolvaptan have received Food and Drug Administration approval for clinical use. The development of nonpeptide AVP V(1a), V(1b) and V(2) antagonists and OT agonists and antagonists has recently been abandoned by Merck, Sanofi and Pfizer. A promising OT antagonist, Retosiban, developed at Glaxo SmithKline is currently in a Phase II clinical trial for the prevention of premature labour. A number of the nonpeptide ligands that were not successful in clinical trials are proving to be valuable as research tools. Peptide agonists and antagonists continue to be very widely used as research tools in this field. In this regard, we present receptor data on some of the most widely used peptide and nonpeptide ligands, as a guide for their use, especially with regard to receptor selectivity and species differences.
Collapse
Affiliation(s)
- M Manning
- Biochemistry and Cancer Biology, University of Toledo College of Medicine, Toledo, OH 43614-2598, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Ingram W, Sintay B, Wiant D, Manning M. SU-E-T-568: A Comparison of Apparent Tumor Volume on Treatment Planning Scans and Daily Volumetric Imaging Scans for Lung SBRT. Med Phys 2011. [DOI: 10.1118/1.3612530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
39
|
Wiant D, Sintay B, Ingram M, Manning M. SU-E-T-538: A Quantitative Evaluation of TomoTherapy Lung SBRT Set-Up Accuracy. Med Phys 2011. [DOI: 10.1118/1.3612500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
40
|
Manning M, Mark R, Anderson P, Akins R, Nair M. Previous Transurethral Resection of the Prostate (TURP) is not a Contraindication for Interstitial High Dose Rate (HDR) Brachytherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
41
|
|
42
|
Manning M, Gotsch U, Minarzyk A, Quail D, Gross A, Pages I, Methfessel HD, Michel MC. How are women with SUI-symptoms treated with duloxetine in real life practice? - preliminary results from a large observational study in Germany. Int J Clin Pract 2009; 63:1724-33. [PMID: 19930333 DOI: 10.1111/j.1742-1241.2009.02186.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND Duloxetine was found safe and effective in the treatment of moderate to severe female stress urinary incontinence (SUI) in controlled clinical trials; complementary data from routine clinical practice are still wanted. OBJECTIVES To explore the use of various initial duloxetine doses by physicians in the treatment of female SUI in routine clinical practice and its implications on drug safety and patients' subjective impression of effectiveness. METHODS Adult women treated with duloxetine for SUI symptoms were documented as part of an ongoing large-scale observational study in Germany. Data collected at baseline, after 4 and 12 weeks, were evaluated by initial doses. Statistics were descriptive, 95% confidence intervals were calculated for adverse event (AE) rates. RESULTS A total of 7888 adult women were treated with duloxetine; their mean age was 61.4 years, body mass index 27 kg/m(2), incontinence episode frequency (IEF) 14.0 per week. Previous SUI treatments were observed in 52.2%, comorbidities in 60.4% of the patients. A total of 90.7% reported reduced frequency of SUI-episodes, 12.1% any AE; nausea (5.7%) and vertigo (1.6%) were reported most frequently. In all, 52.2% of patients were initiated on a duloxetine dose of 40 mg/day. Only minor differences in patient characteristics, effectiveness and tolerability were associated with varying initial duloxetine doses. CONCLUSIONS Many women received lower duloxetine doses than expected based on evidence-based dosing recommendations. Although SUI patients in this study had a higher health risk because of old age and multiple comorbidities than in previous controlled clinical trials, AE rates were lower, possibly because of the observational character of the study and/or the use of rather low doses. Similar AE rates for varying initial doses possibly reflect sensible dose-adjustment to individual needs.
Collapse
Affiliation(s)
- M Manning
- Medical Department, Lilly Deutschland GmbH, Bad Homburg, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Manning M, Mark R, Anderson P, Akins R, Nair M. Previous Transurethral Resection of the Prostate (TURP) is Not a Contraindication for Interstitial High Dose Rate (HDR) Brachytherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
44
|
Manning M, Bryant C, Burney D, Mohamed M, Bell K. A Novel Intraoperative Target Delineation Technique for Permanent Lung Brachytherapy to Enhance Postimplant Dosimetry. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.1000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Manning M. Linda L. Stein and Peter J. Lehu. Literary Research and the American Realism and Naturalism Period: Strategies and Sources. Lanham, Md.: Scarecrow Press, 2009. 319p. alk. paper, $45 (ISBN 9780810861411). LC2008-028963. College & Research Libraries 2009. [DOI: 10.5860/crl.70.5.501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
46
|
Manning M, Aggarwal A, Gao K, Tucker-Kellogg G. Scaling the walls of discovery: using semantic metadata for integrative problem solving. Brief Bioinform 2009; 10:164-76. [DOI: 10.1093/bib/bbp007] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
|
47
|
Manning M. Robert N. Matuozzi and Elizabeth B. Lindsay. Literary Research and the American Moderninst Era: Strategies and Sources. Lanham, Md.: Scarecrow Press, 2008. 173p. alk. paper, $35 (ISBN 081086116). LC2008-15076. College & Research Libraries 2009. [DOI: 10.5860/crl.70.1.89] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
48
|
|
49
|
Mouillac B, Manning M, Durroux T. Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies. Mini Rev Med Chem 2008; 8:996-1005. [PMID: 18782052 DOI: 10.2174/138955708785740607] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Different series of fluorescent agonists and antagonists have been developed and characterized for arginine-vasopressin and oxytocin G protein-coupled receptors. Both cyclic and linear peptide analogs of the neurohypophysial hormones are useful tools for investigating receptor localization and trafficking, analysing receptor structural organization, and developing new receptor-selective high-throughput ligand screening assays.
Collapse
Affiliation(s)
- B Mouillac
- CNRS, UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France.
| | | | | |
Collapse
|
50
|
|